

GARDEREattorneys and counselors • www.gardere.com**FAX RECEIVED**

MAR 18 2002

GROUP 1600

Fax**OFFICIAL**

DATE March 15, 2002

TO	COMPANY	PHONE NO.	FAX NO.
Examiner Frank Choi		703 308-0067	703 308-4556 or 3592

FROM	Edwin S. Flores, Ph.D.	eflores@gardere.com
DIRECT LINE	214-999-4559	
DIRECT FAX	214-999-3559	
CLIENT/MATTER NO.	121753-1005	
TOTAL PAGES (including cover)	8	

RESPONSE AND TERMINAL DISCLAIMER

If you have any problems with this transmission, please call 214.999.4777.

Is this for Service of Documents? No
Please indicate local time deadline:
Confirmation Requested: Yes

COMMENTS:

Please see attached.

Authorized to Charge Deposit Account.

Edwin S. Flores

Confidentiality Note: The documents accompanying this facsimile contain information from the law firm of Gardere Wynne Sewell LLP which is confidential and/or privileged. The information is intended only for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this facsimile is strictly prohibited, and that the documents should be returned to this Firm immediately. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original document to us at no cost to you.

GARDERE WYNNE SEWELL LLP
3000 Thanksgiving Tower, 1601 Elm Street, Dallas, Texas 75201-4761 • 214.999.3000 Phone • 214.999.4667 Fax

Attorney Docket No. 121753-1005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FAX RECEIVED

In re Application of: Lorraine Faxon Meisner

MAR 18 2002

Serial No.: 09/990,611

OFFICIAL

GROUP 1600

Filed: November 21, 2001


For: METHOD FOR TREATMENT OF AGING OR DAMAGED SKIN

Examiner: Frank Choi

Art Group: 1616

Certificate of Facsimile Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being transmitted by facsimile transmission to fax number (703) 308-4556, addressed to: Commissioner for Patents, Washington, D.C. 20231 on March 15, 2002.



Linda L. Gibson
Typed or printed name of person signing certificate

Commissioner for Patents
Washington D.C. 20231

Dear Sir:

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321

Bioderm, Inc., acting through its duly authorized attorney of record, represents that it is the owner of 100 percent of the above-identified Patent Application. In accordance with the provisions of 35 U.S.C. § 253 and Rule 321 of the United States Patent and Trademark Office, Bioderm, Inc. hereby disclaims, except as provided below, the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of U.S. Patent No. 6,217,914, which is owned 100 percent by Bioderm, Inc., and hereby further agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and U.S. Patent No. 6,217,914 are owned. This agreement runs with any patent granted on the instant application and is to be binding on the grantee, its successors or assigns.

04/03/2002 RHARMON 00000004 070153 09990611

01 FC:248 55:06 CH

Attorney Docket No. 121753-1005

PATENT

In making the above disclaimer, Bioderm, Inc. does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154-156, and 173 of U.S. Patent No. 6,217,914 as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Attorney Docket No. 121753-1005

PATENT

The Commissioner is hereby authorized to charge our Deposit Account No. 07-0153 in the amount of \$55.00 for the cost of filing the Terminal Disclaimer and any additional fees that may be required, other than an Issue Fee, or credit any overpayment.

Respectfully submitted,
GARDERE WYNNE SEWELL LLP



Date: March 15, 2002

Edwin S. Flores
Reg. No. 38,453
Attorney for Applicant

Gardere Wynne Sewell LLP
3000 Thanksgiving Tower
1601 Elm Street
Dallas, Texas 75201-4761
(214) 999-3000 - Telephone
(214) 999-4667 - Facsimile